EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study

Ramachandra Sangana, Bernhards Ogutu, Adoke Yeka, Sylvia Kusemererwa, Halidou Tinto, Andre Offianan Toure, Afizi Kibuuka, Moussa Lingani, Carlos Lourenço, Ghyslain Mombo-Ngoma, Videlis Nduba, Tiacoh Landry N'Guessan und 18 weitere

The Journal of Clinical Pharmacology · 2025-02 · 65 (2) · 179-189

DOI: 10.1002/jcph.6138 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 29.09.2024. Verfasst von Ramachandra Sangana und 29 weiteren Autor:innen. Beteiligte Einrichtung: PK Sciences, Biomedical Research, Novartis, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Malaria, Falciparum, Lumefantrine, Antimalarials. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis, Medicines for Malaria Venture, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The novel antimalarial ganaplacide combined with lumefantrine solid dispersion formulation (LUM‐SDF) was effective and well tolerated in the treatment of uncomplicated falciparum malaria in adults, adolescents, and children in a multinational, prospective, randomized, active‐controlled Phase II study conducted between August 2017 and June 2021 (EudraCT 2020‐003284‐25, Clinicaltrials.gov NCT03167242). Pharmacokinetic data from that study are reported here. The trial comprised three parts: a run‐in part in 12 adult/adolescent patients treated with a single dose of ganaplacide 200 mg plus LUM‐SDF 960 mg assessed potential pharmacokinetic (PK) interactions between ganaplacide and lumefantrine; in Part A, adult/adolescent patients received one of the six ganaplacide‐LUM‐SDF regimens or artemether‐lumefantrine; and in Part B, three dose regimens identified in Part A, and artemether‐lumefantrine, were assessed in children aged 2 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, FalciparumLumefantrineAntimalarialsHumansAdolescentChildMaleFemaleAdultChild, PreschoolYoung AdultMiddle AgedProspective StudiesArtemether, Lumefantrine Drug CombinationDrug CombinationsDrug Interactions

Stichwörter der Autor:innen

Plasmodium falciparum malariaganaplacidelumefantrinepharmacokinetics

Substanzen

LumefantrineAntimalarialsArtemether, Lumefantrine Drug CombinationDrug Combinations

Autor:innen und Institutionen

  • PK Sciences, Biomedical Research, Novartis, Cambridge, MA, USA.
  • Centre for Clinical Research, Kenya Medical Research Institute, Kisumu, Kenya and CREATES, Strathmore University, Nairobi, Kenya.
  • Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Medical Research Council/Uganda Virus Resea, rch Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
  • Institut de Recherche en Science de la Santé - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Nanoro, Burkina Faso.
  • Department of Parasitology-Mycology, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire.

Förderung

  • Novartis
  • Medicines for Malaria Venture
  • Bill and Melinda Gates Foundation

Zitieren

APA

Sangana, R., Ogutu, B., Yeka, A., Kusemererwa, S., Tinto, H., Toure, A. O., Kibuuka, A., Lingani, M., Lourenço, C., Mombo-Ngoma, G., Nduba, V., Landry N'Guessan, T., Nassa, G. J. W., Nyantaro, M., Tina, L. O., Anvikar, A., Sinha, A., Kaguthi, G., Fofana, B., …, & Zack, J. (2025). Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study. The Journal of Clinical Pharmacology, 65(2), 179-189. https://doi.org/10.1002/jcph.6138

Vancouver

Sangana R, Ogutu B, Yeka A, Kusemererwa S, Tinto H, Toure AO, et al. Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study. The Journal of Clinical Pharmacology. 2025;65(2):179-189. doi:10.1002/jcph.6138

BibTeX
@article{Sangana2025,
  author = {Sangana, Ramachandra and Ogutu, Bernhards and Yeka, Adoke and Kusemererwa, Sylvia and Tinto, Halidou and Toure, Andre Offianan and Kibuuka, Afizi and Lingani, Moussa and Lourenço, Carlos and Mombo-Ngoma, Ghyslain and Nduba, Videlis and Landry N'Guessan, Tiacoh and Nassa, Guétawendé Job Wilfried and Nyantaro, Mary and Tina, Lucas Otieno and Anvikar, Anup and Sinha, Abhinav and Kaguthi, Grace and Fofana, Bakary and Grobusch, Martin Peter and Gaaloul, Myriam El and Marrast, Anne Claire and Pathan, Rashidkhan and Chikoto, Havana and Csermak, Katalin and Risterucci, Celine and Su, Guoqin and Winnips, Cornelis and Zhang, Jie and Zack, Julia},
  title = {Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  volume = {65},
  number = {2},
  pages = {179--189},
  doi = {10.1002/jcph.6138}
}
Kostenlos starten →